(2R)-2-({4-[(2E)-N-({2-amino-4-oxo-3H,4H-pyrido[3,2-d]pyrimidin-6-yl}methyl)-3-{4-carbamoyl-1-[(2R,3R,4R,5S)-3,4-dihydroxy-5-[(phosphonooxy)methyl]oxolan-2-yl]-1H-imidazol-5-yl}prop-2-enamido]phenyl}formamido)pentanedioic acid

• ChemBase编号: 3683
• 分子式: C32H34N9O15P
• 平均质量: 815.637421
• 单一同位素质量: 815.19119806
• SMILES: NC(=O)c1c(/C=C/C(=O)N(Cc2ccc3nc(N)[nH]c(=O)c3n2)c2ccc(cc2)C(=O)N[C@H](CCC(=O)O)C(=O)O)n(cn1)[C@@H]1O[C@@H](COP(=O)(O)O)[C@H](O)[C@H]1O
• Canonical SMILES: OC(=O)CC[C@H](C(=O)O)NC(=O)c1ccc(cc1)N(C(=O)/C=C/c1n(cnc1C(=O)N)[C@@H]1O[C@H]([C@@H]([C@H]1O)O)COP(=O)(O)O)Cc1ccc2c(n1)c(=O)[nH]c(n2)N
• InChI: InChI=1S/C32H34N9O15P/c33-27(47)24-19(41(13-35-24)30-26(46)25(45)20(56-30)12-55-57(52,53)54)8-9-21(42)40(11-15-3-6-17-23(36-15)29(49)39-32(34)38-17)16-4-1-14(2-5-16)28(48)37-18(31(50)51)7-10-22(43)44/h1-6,8-9,13,18,20,25-26,30,45-46H,7,10-12H2,(H2,33,47)(H,37,48)(H,43,44)(H,50,51)(H2,52,53,54)(H3,34,38,39,49)/b9-8+/t18-,20+,25+,26-,30-/m1/s1
• InChIKey: XRZABKCMPVBQFX-PXOKFWMZSA-N

名称和登记号

名称

• IUPAC标准名: (2R)-2-({4-[(2E)-N-({2-amino-4-oxo-3H,4H-pyrido[3,2-d]pyrimidin-6-yl}methyl)-3-{4-carbamoyl-1-[(2R,3R,4R,5S)-3,4-dihydroxy-5-[(phosphonooxy)methyl]oxolan-2-yl]-1H-imidazol-5-yl}prop-2-enamido]phenyl}formamido)pentanedioic acid
• IUPAC传统名: (2R)-2-({4-[(2E)-N-({2-amino-4-oxo-3H-pyrido[3,2-d]pyrimidin-6-yl}methyl)-3-{5-carbamoyl-3-[(2R,3R,4R,5S)-3,4-dihydroxy-5-[(phosphonooxy)methyl]oxolan-2-yl]imidazol-4-yl}prop-2-enamido]phenyl}formamido)pentanedioic acid
• 别名: Beta-Dadf, Msa, Multisubstrate Adduct Inhibitor

登记号

• PubChem SID: 46507189; 160967121
• PubChem CID: 46936874

理论计算性质

JChem

• Acid pKa: 1.2095056
• 质子受体: 18
• 质子供体: 10
• LogD (pH = 5.5): -8.448875
• LogD (pH = 7.4): -13.200915
• Log P: -3.506909
• 摩尔折射率: 190.4972 cm^3
• 极化性: 71.58534 Å^3
• 极化表面积: 381.74 Å^2
• 可自由旋转的化学键: 16
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: -1.02
• LOG S: -3.86
• 溶解度: 1.13e-01 g/l

详细说明

DrugBank - DB04057

Drug information: experimental